LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First in Diagnostics – Solid-State Technology Device Accredited in EU

By LabMedica International staff writers
Posted on 06 Oct 2014
Image:  The CoagMax PT/INR system – the first to incorporate solid-state, MEMS technology into a disposable diagnostic test strip – enables rapid-test monitoring of blood clotting speed in an easy-to-use, portable format. Left: The CoagMax reader with inserted strip; Right: Two PT/INR sensor strips (Photo courtesy of Microvisk).
Image: The CoagMax PT/INR system – the first to incorporate solid-state, MEMS technology into a disposable diagnostic test strip – enables rapid-test monitoring of blood clotting speed in an easy-to-use, portable format. Left: The CoagMax reader with inserted strip; Right: Two PT/INR sensor strips (Photo courtesy of Microvisk).
The CE marking has been given for healthcare professional use of a new PT/INR blood-testing disposable diagnostic strip as part of the world’s first accredited diagnostic device based on a micro-electromechanical system (MEMS).

The CE marking accreditation, achieved by Microvisk Ltd (St. Asaph, UK) for its CoagMax PT/INR system, is a major step forward in blood testing technology. Microvisk’s patented microcantilever sensor technology determines blood clotting speed from a finger-prick sample, with results displayed on its compact CoagMax handheld reader. The PT/INR strip, which uses the standard international PT (Prothrombin Time) or INR (International Normalized Ratio) test on a drop of patient’s whole blood from a finger prick, measures fluid viscosity, combining accurate, dependable, lab-quality results with exceptional ease of use. The strip sensors detect blood changes to a gel-like substance and assess whether viscosity is within acceptable range for the patient’s medication.

Patient clotting speed is measured by multilayered MEMS sensors, incorporating a cantilever on the strip surface to measure the fluid viscosity. An embedded microchip stores calibration data and the CoagMax reader automatically rejects any strip compromised by prior use.

“CE marking for CoagMax takes us close to the runway for product launch to the European healthcare professional market and beyond,” said Microvisk CEO Jim Thurlow. He added, “The achievement of CE marking of a medical diagnostic device based on a tiny MEMS sensor is a major milestone for Microvisk – and opens up further possibilities for this pioneering technology.”

Initial application of the technology is for monitoring patients taking anticoagulants such as Warfarin, to minimize risk from life-threatening blood clots and help manage correct dosage. Microvisk’s platform technology is unique in medical diagnostics as a robust, solid-state system with the simplicity to revolutionize point-of-care and home testing. With patients on anticoagulants needing regular tests to confirm correct dosage levels, there’s an increasing trend for self-testing at home. The Microvisk CoagMax reader and PT/INR strip enable patients to quickly and conveniently test blood clotting, as diabetics test for glucose.

The CoagMax PT/INR system is distinct from other existing technology, which relies on more complex and less user-friendly optical analysis or chemical reaction-based measurement. The CoagMax meter reduces healthcare cost as well as patient time and inconvenience for clinic attendance and laboratory services. Requiring only 8 µL of blood, less than competing systems, also means less pain for users.

Related Links:

Microvisk 


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gel Cards
DG Gel Cards

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more